dovitinib
Small moleculeexperimental
Fibroblast growth factor receptor 1 (FGFR-1), also known as basic fibroblast growth factor receptor 1, fms-related tyrosine kinase-2 / Pfeiffer syndrome, and CD331, is a receptor tyrosine kinase whose ligands are specific members of the fibroblast growth factor family. FGFR-1 has been shown to be associated with Pfeiffer syndrome, and clonal eosinophilias. — Wikipedia
Clinical trial activity
57 trials · 37 clinical orgs · 0 marketing orgs
Phase 1
25
Phase 2
34
Phase 3
2
Phase 4
0
Earliest trial started Dec 1, 2003 (NCT01270906)
Timeline
Indications
Studied for
- Adenocarcinoma, Scirrhous · Phase 2
- Adrenocortical Carcinoma · Phase 2
- Brain Neoplasms · Phase 2
- Breast Neoplasms · Phase 2
- Carcinoma, Adenoid Cystic · Phase 2
- Carcinoma, Hepatocellular · Phase 2
- Carcinoma, Islet Cell · Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Carcinoma, Renal Cell · Phase 3
- Carcinoma, Transitional Cell · Phase 2
- Colorectal Neoplasms · Phase 2
- Endometrial Neoplasms · Phase 2
- Gastrinoma · Phase 2
- Gastrointestinal Stromal Tumors · Phase 2
- Glioblastoma · Phase 2
- Glioma · Phase 2
- Gliosarcoma · Phase 2
- Glucagonoma · Phase 2
- Insulinoma · Phase 2
- Leukemia, Myeloid, Acute · Phase 1
- Linitis Plastica · Phase 2
- Liver Diseases · Phase 1
- Melanoma · Phase 1/Phase 2
- Mesothelioma · Phase 2
- Multiple Myeloma · Phase 2
- Neoplasm Metastasis · Phase 2
- Neoplasms · Phase 2/Phase 3
- Neoplasms by Site · Phase 2
- Pancreatic Neoplasms · Phase 2
- Pheochromocytoma · Phase 2
- Prostatic Neoplasms · Phase 2
- Salivary Gland Neoplasms · Phase 2
- Somatostatinoma · Phase 2
- Stomach Diseases · Phase 2
- Stomach Neoplasms · Phase 2
- Thyroid Neoplasms · Phase 2
- Urinary Bladder Neoplasms · Phase 2
- Vascular Endothelial Growth Factor A · Phase 2
- von Hippel-Lindau Disease · Phase 2
Mechanism of action
- Fibroblast growth factor receptor 3INHIBITOR
FGFR3 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1- Mol. weight
- 392.44 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL522892 ↗
- WikipediaFibroblast growth factor receptor 1 ↗
- ChEMBLCHEMBL2103806 ↗
Also known as
- 4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl)quinolin-2(1h)-one
- chir258
- chir258
- chir 258
- chir-258
- chir-258
- chir-258
- chir-258
- dovitinib
- dovitinib
- dovitinib
- dovitinib
- dovitinib
- dovitinib lactate
- dovitinib lactate
- dovitinib lactate
- gfki-258
- gfki-258
- nvp-tki258
- nvp-tki258
- tki258
- tki 258
- tki-258
- tki-258
- tki-258
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05571969 | Phase 1 | Oct 20, 2022 | Allarity Therapeutics, Amarex Clinical Research |
| NCT02268435 | Phase 1 | Mar 1, 2015 | University of Ulsan |
| NCT02048943 | Phase 1 | Mar 1, 2015 | National Cancer Institute (NCI), Novartis, State University of New York, Buffalo |
| NCT02108782 | Phase 2 | Oct 1, 2014 | Academic and Community Cancer Research United, National Cancer Institute (NCI) |
| NCT02116803 | Phase 2/Phase 3 (Phase 3) | May 28, 2014 | Novartis |
| NCT01994590 | Phase 2 | May 19, 2014 | Novartis, University of Texas at Houston |
| NCT02065323 | Phase 2 | Feb 3, 2014 | Comprehensive Cancer Centers of Nevada |
| NCT01888965 | Phase 2 | Oct 1, 2013 | Georgetown University, Novartis |
| NCT01972750 | Phase 1 | Oct 1, 2013 | University of Bonn |
| NCT01921673 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2013 | Novartis, University of Ulsan |
| NCT01831726 | Phase 2 | Aug 1, 2013 | Novartis |
| NCT01700270 | Phase 1 | May 1, 2013 | Novartis |
| NCT01769547 | Phase 2 | Mar 1, 2013 | McMaster University, Novartis, University of Ottawa |
| NCT01861197 | Phase 2 | Mar 1, 2013 | Sungkyunkwan University |
| NCT01732107 | Phase 2 | Mar 1, 2013 | Hoosier Cancer Research Network, Johns Hopkins University, Novartis |
| NCT01676714 | Phase 2 | Feb 1, 2013 | Novartis, University of California, Davis |
| NCT01680796 | Phase 1 | Feb 1, 2013 | Novartis, University of Florida |
| NCT01964144 | Phase 2 | Jan 1, 2013 | Yonsei University |
| NCT01753713 | Phase 2 | Dec 1, 2012 | Case Western Reserve University, National Cancer Institute (NCI), Novartis, University of Rochester |
| NCT01266070 | Phase 2 | Nov 1, 2012 | Novartis, University of Texas at Houston |
Showing 20 of 57 trials
Page 1 / 3
Organizations
Research & Development (37)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novartis | For profit | 44 | 24 | 3 | 2003 |
| National Cancer Institute (NCI) | Government | 4 | 0 | 2 | 2012 |
| University of Texas at Houston | Academic/Hospital | 4 | 3 | 2 | 2012 |
| University of Ulsan | Academic/Hospital | 4 | 4 | 2 | 2011 |
| Georgetown University | Academic/Hospital | 2 | 2 | 1 | 2012 |
| McMaster University | Academic/Hospital | 2 | 2 | 1 | 2012 |
| Seoul National University | Academic/Hospital | 2 | 2 | 1 | 2011 |
| State University of New York, Buffalo | Academic/Hospital | 2 | 2 | 1 | 2012 |
| Academic and Community Cancer Research United | Academic/Hospital | 1 | 1 | 1 | 2014 |
| Allarity Therapeutics | For profit | 1 | 1 | 1 | 2022 |
| Amarex Clinical Research | For profit | 1 | 0 | 1 | 2022 |
| Auckland District Health Board | Government | 1 | 1 | 1 | 2012 |
| Case Western Reserve University | Academic/Hospital | 1 | 1 | 1 | 2012 |
| Chiron | For profit | 1 | 0 | 1 | 2003 |
| Comprehensive Cancer Centers of Nevada | Academic/Hospital | 1 | 1 | 1 | 2014 |
| Genentech | For profit | 1 | 0 | 1 | 2012 |
| Government of Singapore | Government | 1 | 1 | 1 | 2011 |
| Hoosier Cancer Research Network | Academic/Hospital | 1 | 0 | 1 | 2013 |
| Hospital Universitario de Fuenlabrada | Academic/Hospital | 1 | 0 | 1 | 2012 |
| IGENZ, Ltd. | For profit | 1 | 0 | 1 | 2012 |
37 organizations
Page 1 / 2